세계의 주의력결핍 과잉행동장애 시장 : 부문별 예측(2025-2030년)

The Attention Deficit Hyperactivity Disorder Market was valued at USD 14.99 billion in 2023, expected to reach USD 15.61 billion in 2024, and is projected to grow at a CAGR of 4.18%, to USD 19.98 billion by 2030.

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity, impacting children's educational performance and adults' professional productivity. The scope of market analysis for ADHD encompasses pharmaceuticals, behavioral therapy, and digital therapies, driven by rising awareness, improved diagnostic procedures, and increased prevalence. The necessity and application of ADHD treatments are based on enhancing patients' life quality, making them crucial for households, educational institutions, and workplaces. The end-use scope includes pediatric and adult patients, educational settings, healthcare providers, and research labs. The market is propelled by increasing incidence rates, sophisticated treatment options, and heightened societal recognition of mental health needs. Key growth influencers include technological advancements like telehealth services, personalized medicine, and government healthcare initiatives. Opportunistically, the evolving acceptance of novel treatments like digital therapeutics and non-invasive neurofeedback therapies presents unexplored opportunities. Market players are recommended to invest in R&D for these emerging technologies and expand collaborations with healthcare facilities and academic institutions for broader product dissemination. Despite the vibrant growth trajectory, challenges such as stigmatization, varied diagnosis standards across regions, and high treatment costs persist. Additionally, regulatory hurdles for new drug approvals and the complexity of gaining widespread insurance coverage pose barriers. Innovation areas ripe for exploration include AI-driven diagnostic tools, cost-effective treatment delivery models, and awareness campaigns to battle stigma. The ADHD market is inherently dynamic, shaped by intersecting healthcare, technological, and sociocultural trends. Businesses positioning themselves at the convergence of these domains with investment in patient-centered innovations and strategic partnerships stand the best chance of thriving in this sector. Companies should maintain adaptability to swiftly align with evolving regulatory standards and consumer expectations to capture market potential effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Attention Deficit Hyperactivity Disorder Market

The Attention Deficit Hyperactivity Disorder Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of attention deficit hyperactivity disorder among children and adults worldwide
  • Advancements in diagnostic tools and techniques for early detection of attention deficit hyperactivity disorder
  • Growing awareness and educational initiatives about attention deficit hyperactivity disorder among parents and educators
  • Surge in research and development activities for innovative treatment options in attention deficit hyperactivity disorder market
• Market Restraints
  • Lack of qualified mental health professionals with expertise in ADHD leading to delayed or incorrect diagnosis and treatment
• Market Opportunities
  • Innovative pharmaceutical formulations targeting symptom-specific relief for different age groups with ADHD
  • Customized educational programs and tools designed to enhance learning experiences for children with ADHD
  • Workplace accommodation solutions for adults with ADHD focusing on productivity and mental health improvement
• Market Challenges
  • High cost of ADHD diagnosis and treatment combined with limited insurance coverage reduces accessibility for patients

Porter's Five Forces: A Strategic Tool for Navigating the Attention Deficit Hyperactivity Disorder Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Attention Deficit Hyperactivity Disorder Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Attention Deficit Hyperactivity Disorder Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Attention Deficit Hyperactivity Disorder Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Attention Deficit Hyperactivity Disorder Market

A detailed market share analysis in the Attention Deficit Hyperactivity Disorder Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Attention Deficit Hyperactivity Disorder Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Attention Deficit Hyperactivity Disorder Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Attention Deficit Hyperactivity Disorder Market

A strategic analysis of the Attention Deficit Hyperactivity Disorder Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Attention Deficit Hyperactivity Disorder Market, highlighting leading vendors and their innovative profiles. These include Akili Interactive Labs, Inc., Austedo Pharmaceuticals, Cingulate Therapeutics, LLC, Eli Lilly and Company, Ironshore Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., KemPharm, Inc., Medice Arzneimittel Putter GmbH & Co. KG, Neos Therapeutics, Inc., NeuroSigma, Inc., NLS Pharmaceutics AG, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Shire Plc, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Attention Deficit Hyperactivity Disorder Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapies, market is studied across Pharmacotherapy and Psychotherapy. The Pharmacotherapy is further studied across Non-Stimulants and Stimulants. The Psychotherapy is further studied across Behavioral Therapy, Cognitive Behavioral Therapy, Family Therapy, and Social Skills Training.
• Based on Patient Type, market is studied across In-Patients and Out-Patients.
• Based on Application, market is studied across Attention Deficit Disorder and Hyperactive Disorder.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of attention deficit hyperactivity disorder among children and adults worldwide
    • 5.1.1.2. Advancements in diagnostic tools and techniques for early detection of attention deficit hyperactivity disorder
    • 5.1.1.3. Growing awareness and educational initiatives about attention deficit hyperactivity disorder among parents and educators
    • 5.1.1.4. Surge in research and development activities for innovative treatment options in attention deficit hyperactivity disorder market
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of qualified mental health professionals with expertise in ADHD leading to delayed or incorrect diagnosis and treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Innovative pharmaceutical formulations targeting symptom-specific relief for different age groups with ADHD
    • 5.1.3.2. Customized educational programs and tools designed to enhance learning experiences for children with ADHD
    • 5.1.3.3. Workplace accommodation solutions for adults with ADHD focusing on productivity and mental health improvement
  • 5.1.4. Challenges
    • 5.1.4.1. High cost of ADHD diagnosis and treatment combined with limited insurance coverage reduces accessibility for patients
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Attention Deficit Hyperactivity Disorder Market, by Therapies

• 6.1. Introduction
• 6.2. Pharmacotherapy
  • 6.2.1. Non-Stimulants
  • 6.2.2. Stimulants
• 6.3. Psychotherapy
  • 6.3.1. Behavioral Therapy
  • 6.3.2. Cognitive Behavioral Therapy
  • 6.3.3. Family Therapy
  • 6.3.4. Social Skills Training

7. Attention Deficit Hyperactivity Disorder Market, by Patient Type

• 7.1. Introduction
• 7.2. In-Patients
• 7.3. Out-Patients

8. Attention Deficit Hyperactivity Disorder Market, by Application

• 8.1. Introduction
• 8.2. Attention Deficit Disorder
• 8.3. Hyperactive Disorder

9. Americas Attention Deficit Hyperactivity Disorder Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Attention Deficit Hyperactivity Disorder Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Attention Deficit Hyperactivity Disorder Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Akili Interactive Labs, Inc.
• 2. Austedo Pharmaceuticals
• 3. Cingulate Therapeutics, LLC
• 4. Eli Lilly and Company
• 5. Ironshore Pharmaceuticals Inc.
• 6. Janssen Pharmaceuticals, Inc.
• 7. KemPharm, Inc.
• 8. Medice Arzneimittel Putter GmbH & Co. KG
• 9. Neos Therapeutics, Inc.
• 10. NeuroSigma, Inc.
• 11. NLS Pharmaceutics AG
• 12. Novartis AG
• 13. Otsuka Pharmaceutical Co., Ltd.
• 14. Pfizer Inc.
• 15. Shire Plc
• 16. Sunovion Pharmaceuticals Inc.
• 17. Supernus Pharmaceuticals, Inc.
• 18. Takeda Pharmaceutical Company Limited